Conventional therapy for @entity1358 using interferon (IFN) has shown limited antitumor action. The IFN-loaded @entity1346 formulation (IFN-SF) is a sustained-release formulation of @entity1 lymphoblastoid IFN, with a medical grade @entity1346 elastomer used as the carrier material. We evaluated the antitumor effect of IFN-SF on @entity1 @entity1358 cell line (KU-2) transplanted to @entity19 . The treatment was started when the @entity5 nodules had grown 6 to 8 mm in diameter. IFN-SF, on an aqueous solution of IFN, was given by subcutaneous or peritumoral injection. Antitumor effects were evaluated according to @entity5 weights calculated as (long diameter) x (short diameter)2/2 in 7 groups consisting of 6 mice each. Serum IFN levels remained detectable up to 30 days after subcutaneous injection of IFN-SF. IFN-SF administered by the subcutaneous and peritumor route significantly inhibited growth of the @entity5 when compared with @entity5 growth in the untreated @entity19 and @entity19 treated with aqueous IFN solution. IFN-SF had equivalent inhibitory effects on @entity5 growth by peritumor and subcutaneous injection. Results indicated that the use of IFN-SF could reduce the frequency of injections and provide better treatment of @entity1 with @entity1358 because of its long-acting effect when it is used systemically.

Antitumor effects of an interferon-loaded XXXX formulation in @entity1 @entity1358 in @entity19 .

@entity1 :: ('9606', 'Species') :: ['human', 'patients'] @entity19 :: ('10090', 'Species') :: ['mice', 'nude mice'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma'] @entity1346 :: ('MESH:D012828', 'Chemical') :: ['silicone']
@entity1346 :: (MESH:D012828,Chemical) :: ['silicone']
